Today, we are announcing plans to build a new flagship manufacturing hub in North Carolina. Expected to create 700 new jobs, and thousands more across the supply chain, this hub will expand end-to-end manufacturing capabilities across all our therapeutic areas in the US. Representing a significant milestone in our $23 billion investment in US infrastructure, this hub will strengthen our supply chain and help ensure medicines for US patients are manufactured in the US and delivered to patients across the country at scale. 🔗 To learn more about our investment read here: https://lnkd.in/dMgT3iDS or swipe below. 👇
Novartis US
Pharmaceutical Manufacturing
East Hanover, New Jersey 184,052 followers
Transforming people’s lives by reimagining medicine.
About us
We are an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. See our community guidelines: https://go.novartis.social/4bqbjuA
- Website
-
https://www.novartis.us/
External link for Novartis US
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- East Hanover, New Jersey
- Founded
- 1996
- Specialties
- Research, Innovation, Quality, Sustainability, Innovative Medicines, Generic Medicines and Biosimilars, Unique Portfolio Focuses & Broad Healthcare Portfolio, Cell & Gene Therapy, and Data & Digital
Updates
-
How can clinical trials better reflect the realities of disease and help improve patient outcomes? At the recent American Heart Association Scientific Sessions 2025, our US Medical Head of Cardiovascular Renal and Metabolism (CRM), Cesar Cerezo, took part in a compelling panel discussion focused on the future of clinical trial design to address the complexities of cardiovascular-kidney-metabolic (CKM) health. Novartis is a supporting sponsor of the American Heart Association’s Cardiovascular-Kidney-Metabolic Health Initiative because we believe that interconnected diseases require interconnected thinking. 📸 Swipe through for moments from the panel. #AHA25 #NovartisUS
-
-
Cardiovascular disease remains the leading cause of death in the US - and too often, health outcomes are determined by zip code. Through our HEART Initiative with Meharry Medical College School of Global Health, we're addressing the clinical and non-clinical barriers to optimal cardiovascular health in Nashville, Detroit, and San Bernardino. We know lasting change doesn't happen alone. This partnership empowers communities to co-create solutions and build pathways to better heart health. Learn more: https://lnkd.in/eEpsrGvY #NovartisUS #CommunityHealth
-
How can we harness AI and data-driven insights to get life-changing medicines to patients as simply and seamlessly as possible?🧪 That’s the question driving Eden Wells, Chief Insights and Decision Science Officer at Novartis US, as she and her team harness emerging technologies, data, behavioral science and analytics to rewire how Novartis makes decisions to help close gaps in care. Learn how Eden and her team are working to simplify healthcare decision making, so patients can get diagnosed earlier and we can broaden access to vital medicines: 🔗https://lnkd.in/eq2BZ7Y9 Follow along as we share more from Take 5, our new series spotlighting what drives and inspires leaders of Novartis US to improve healthcare. #NovartisUS #NovartisTake5
-
That's a wrap on a whirlwind week for our Cardiovascular, Renal and Metabolic (CRM) team! We didn't just show up strong at American Society of Nephrology #KidneyWk or American Heart Association #AHA25 - we showed up at both. Same week. Same mission. When it comes to interconnected diseases, we believe in interconnected thinking. Together, we're not just advancing #cardiovascular and #kidney care - we're striving to rewrite what's possible for millions of people with CRM diseases. #NovartisUS
-
-
-
-
-
+3
-
-
Partnership drives progress. Our work with patient advocacy groups is critical to advancing care for people living with autoimmune and other immune-mediated conditions, like chronic spontaneous urticaria (CSU). These organizations bring invaluable expertise and patient insights that help shape everything we do. This year in CSU, we’ve collaborated closely with advocacy groups on four priorities: understanding the patient journey, addressing health disparities, empowering patients, and helping cultivate community. Through close collaboration, we're building patient-centered solutions to drive meaningful impact for this community. Learn more about our work: https://lnkd.in/eKZF-fCc #NovartisUS
-
How can digital accessibility build a stronger workforce community? Last week, our associates set out to uncover this together at our fourth annual Access, Belonging, Leadership, Empowerment (A.B.L.E.) Disability Inclusion Summit in person and remotely. “By elevating voices from across our community and engaging in conversation, we reaffirm our commitment to access, belonging, leadership, and empowerment—not just for one day, but every day for all our colleagues,” shares Marion Brooks, MBA, US Country Head, Culture & People Experience at Novartis. “The A.B.L.E. Summit is a meaningful opportunity to listen with intention, learn from one another, and continue shaping a workplace that works for all our colleagues and where everyone feels seen, valued, and supported.” A huge thank you to our inspiring panel speakers Jeff Wissel, Chief Accessibility Officer at Disability:IN, Mary Treacy, Novartis VP, Global Head of Data, Digital & IT, and participants Binding Minds Inc. (Certified Disability Owned Business Enterprise), Kate O'Connor, CPACC, and Catherine Sherry, CPACC and Wanda Sims for her leadership at this event. Together, we’re building a workplace where every individual thrives. #NovartisUS
-
-
Thanks so much for visiting our Novartis US LinkedIn community! While we love hearing from all community members, please understand that due to the regulated nature of our industry, there are certain conversations we cannot engage in on our channels. To maintain a positive community 👏 and ensure a safe space for all, we may remove comments that violate our community guidelines. Please refer here for them: https://lnkd.in/ev_vacb4
-
A veteran’s journey from service to leadership. 🪖 Meet Matthew Baca, our Indianapolis Head of Site Operations. Matt has carried the leadership, discipline, and resilience he gained in the military into his role driving manufacturing operations for innovative medicines. We’re proud to honor veterans like Matt, whose dedication and contributions inspire us every day. Thank you to all who have served and continue to serve. 🔗Read more: https://lnkd.in/ehE7Z9uV #NovartisUS #VeteransDay
-
Today, we are announcing the opening of a new state-of-the-art radioligand therapy (RLT) manufacturing facility in Carlsbad, California. Representing a key milestone in our $23 billion US expansion plan over the next five years, the opening of our third RLT site allows us to meet future demand, continue on-time delivery to patients across the western US, and augments our world-class supply chain capabilities. By reimagining how innovation reaches patients, this opening reflects our strong investment in the US and our commitment to bringing this pioneering treatment to more patients across the country. 🔗 Discover how: https://lnkd.in/dxDQVCra #NovartisUS #ReimaginingMedicine